Introduction
Brown adipose tissue (BAT), a key non-shivering thermogenic tissue, plays a crucial role in adaptive thermogenesis in small mammals and newborn infants, and has long been considered to have no physiological relevance in adult humans. 1 However, recent study using positron emission tomography and computed tomography (PET/CT) have revealed that BAT is occasionally present and is active in adulthood during cold acclimation. 2 BAT is a highly energetic component of adipose that uses glucose and fatty acids as fuel, and is inversely correlated with BMI in humans, in contrast to white adipose tissue (WAT). 3 These findings have led to the notion that activation of BAT is a potential therapeutic strategy to prevent the development of obesity and metabolic disease. [4] [5] [6] [7] The effects of BAT activation on atherosclerosis have recently been investigated; however, experimental findings remain controversial. [8] [9] [10] Although BAT activation by cold acclimation significantly decreased plasma triglyceride, it increased the plasma levels of small low-density lipoprotein (LDL) remnants, leading to atherosclerotic plaque growth in apolipoprotein E deficient (apoE 2/2 ) mice accompanied by marked reduction of plasma adiponectin levels. 8 In contrast, BAT activation by b3-adrenergic receptor (AR) stimulation, which mimics cold exposure, inhibits the development of atherosclerosis in APOE*3-Leiden.CETP mice, but not in hyperlipidemic apoE 2/2 mice or LDL receptor deficient (LDLR 2/2 ) mice. 9 They showed that through the apoE-LDLR-dependent clearance pathway, BAT activation reduced plasma cholesterol, as well as triglyceride, by accelerating hepatic clearance of cholesterol-rich remnants.
Previous studies have investigated the anti-atherogenic effect of activated BAT by focusing on augmented energy expenditure, with a consequent improvement in lipid homeostasis; however, BAT, as well as WAT, has recently been identified as an endocrine organ that regulates metabolic homeostasis. 11 BAT produces and releases various kinds of adipokines, termed 'batokines', which have different actions from those in WAT. 5, 6 Gunawardana et al. showed that adiponectin, leptin, and insulin growth factor-1 (IGF-1) was significantly increased in BATtransplanted mice, which corrected glucose homeostasis in type 1 diabetic rats. 5 A recent study by Stanford et al. 6 showed that BAT transplantation stimulated the production and release of fibroblast growth factor 21 (FGF-21) in endogenous BAT in an interleukin 6 (IL-6)-dependent manner, which stimulated adiponectin production in WAT, leading to improvement in glucose homeostasis and insulin sensitivity. However, it remains to be determined whether activated BAT could function as an endocrine organ to inhibit atherosclerotic plaque development.
Here, we showed, for the first time, that BAT transplantation exerts anti-atherogenic effects, accompanied by enhanced gene and protein expression of FGF-21 in endogenous BAT. Serum levels of FGF-21 were also increased in BAT-transplanted mice along with a higher concentration of circulating adiponectin, which was inversely correlated with atherosclerotic lesions. Treatment with a b3-AR blocker completely abolished the anti-atherogenic effect of transplanted BAT accompanied by reduction of serum FGF-21 and adiponectin, suggesting that BAT transplantation elevates circulating FGF-21 by b3-AR-mediated activation of endogenous BAT, thereby preventing atherosclerosis development through activation of the FGF-21-adiponectin axis. Our findings suggest that BAT could function as an endocrine organ to inhibit atherosclerosis and its activation could be a potential therapeutic strategy to prevent cardiovascular diseases, as well as obesity and metabolic diseases, in adults.
Methods
For detailed experimental procedures, see Supplementary material online.
Experimental animals
All experiments were performed with strict adherence to 'Directive 2010/63/EU' of the European Parliament and to the Guidelines for /J background. C57BL/6-Tg (CAG-EGFP) C14-Y01-FM131Osb mice were kindly provided by Prof. M. Okabe (Osaka University). BAT transplantation was performed as described previously in, 6 and studied in the following four protocols: (i) transplantation of interscapular BAT from GFP-transgenic mice (C57BL/6) into apoE A laparotomy was performed under sterile conditions with the assistance of an operating stereomicroscope. Finally, the musculofascial and skin incisions were sutured. Mice that were sham operated underwent the same procedure without receiving BAT or eWAT. BATtransplanted, WAT-transplanted, and sham control apoE 2/2 mice were fed a high-cholesterol diet (13.6% fat, 1.25% cholesterol; Oriental Yeast Co., Tokyo, Japan) until 24 weeks of age. In the experiment of protocol 3, nonselective b3-AR blocker (1 mg/kg/d, SR59230A, Sigma), or saline were administered using an osmotic minipump until 24 weeks of age, as described previously in. 12 Osmotic minipump was implanted under anesthesia induced by inhalation of isoflurane (2%, 0.2 mL/min). The animals were housed in a room that was maintained at 22 C under a 12-h light/ dark cycle and were provided with drinking water ad libitum. At 24 weeks, mice were sacrificed by trans-cardiac perfusion of physiological saline solution under anesthesia induced by inhalation of isoflurane (2%, 0.2 mL/min), and atherosclerotic lesions of the aorta were evaluated.
Serum lipid analysis
Measurements of total cholesterol, triglyceride, LDL-cholesterol, and high-density lipoprotein (HDL)-cholesterol were outsourced to SRL, Tokyo, Japan. In the homologous BAT or eWAT transplantation of apoE 2/2 mice (protocol iv), plasma lipoproteins were analyzed by HPLC, using molecular sieve columns (Skylight Biotech, Akita, Japan). Lipoprotein subclasses were defined based on lipoprotein particle size (diameter), as described previously in. 13 
Quantitative measurement of atherosclerotic lesions
Mice were euthanized, and atherosclerotic lesions were analyzed at 24 weeks. The whole aortic lesion area in each animal was expressed as a 
Real-time PCR
Total RNA was isolated from adipose tissue and reverse transcribed to prepare cDNA. Real-time PCR was performed on a Thermal Cycler Dice (Takara Bio, Shiga, Japan), using SYBR Premix Ex Taq 2 (Takara Bio, Shiga, Japan). Dissociation curves were examined for the aberrant formation of primer dimers. PCR-amplified products were electrophoresed on 2% agarose gels to confirm the presence of a single amplicon. Threshold cycle (CT) values were normalized to GAPDH, and relative expression was calculated by the DDCT method. Fold change was calculated by normalizing relative expression to sham control mice, which was arbitrarily standardized to one.
Statistical analysis
We performed the Kolmogorov-Smirnov Test for the normality of all continuous variables, and if the p-value was more than 0.05, which indicated all data was normally distributed and could be expressed as mean ± S.E. Mean values were compared using analysis of variance (ANOVA). If statistical significance was found, the Tukey-Kramer test was performed to analyze differences between the groups. For correlation studies, P value and Spearman regression coefficient (r) are shown as the best-fit line generated by STATCEL2 (OMS, Saitama, Japan). P < 0.05 was considered statistically significant.
Results

Atherosclerotic lesion development is reduced in BAT-transplanted apoE À/À mice
We first transplanted interscapular BAT from 12-week-old C57BL/6-Tg (CAG-EGFP) C14-Y01-FM131Osb mice into the visceral cavity of agematched apoE 2/2 mice (B6.129P2-Apoe tm1Unc /J). Histochemical analysis of the grafted BAT after 12 weeks of transplantation revealed the successful engraftment of transplanted BAT (see Supplementary material online, Figure S1 ). We then examined the impact of BAT transplantation on atherosclerosis between wild-type donor mice and apoE 2/2 recipient mice (B6.129P2-Apoe tm1Unc N11). Atherosclerotic lesions in whole aortas after 12 weeks of transplantation was markedly reduced by 20% in BAT-transplanted mice compared with control mice ( Figure 1A and B) , while the percentage of plaque and oil-red O-positive area in the aortic root were unchanged between the two groups ( Figure 1C and D) .
Percentages of Mac-3-and VCAM-1-positive areas were comparable between the two groups (see Supplementary material online, Figure S2A and B). Mean body weight was modestly, but significantly, smaller than control mice (28.6 ± 0.7 g vs. 31 .8 ± 1.2 g, P < 0.05, see Supplementary material online, Figure S2C ), while cumulative caloric intake did not differ (see Supplementary material online, Figure S2D ). The hemodynamic parameters showed a significant increase in both systolic and diastolic blood pressure in BAT-transplanted mice with no difference in heart rate (see Supplementary material online, Figure S2E ). Lipid profiles, with the exception of serum triglyceride levels, were comparable (see Supplementary material online, Figure S2F ). To confirm that present BAT transplantation model appropriately response as well as earlier transplantation models, 6 glucose homeostasis and energy expenditure were examined. In agreement with previous reports showing that BAT transplantation improves glucose tolerance along with the enhanced energy expenditure, 6 the intraperitoneal glucose tolerance test showed significant improvement in BAT-transplanted apoE 2/2 mice (B6.129P2-
Apoe tm1Unc
/J), while insulin sensitivity exhibited no difference (Figure 1E and F). As expected, oxygen consumption and energy expenditure were significantly increased in BAT-transplanted apoE 2/2 mice (B6.129P2-
/J) ( Figure 1G and H). To exclude the possibility that differences in genetic background between the donor (wild-type mice) and recipient (apoE 2/2 mice) could affect our results, homologous transplantation of apoE 2/2 mice on B6.129P2-Apoe tm1Unc /J background was performed. As shown in Figure  2A and B, BAT transplanted mice showed significantly smaller atherosclerotic lesions area than sham control mice. These findings demonstrate that anti-atherogenic action of BAT transplantation is not due to the difference in genetic background between donor and recipient mice. Furthermore, eWAT was transplanted into the recipient apoE 2/2 mice with the same genetic background. Atherosclerotic lesion area showed no difference between eWAT-transplanted apoE 2/2 mice and sham control mice ( Figure 2A and B). Although endogenous BAT and inguinal WAT (iWAT) weights were significantly lower compared with sham control and eWAT-transplanted mice (see Supplementary material online, Figure S3 ), lipid profile did not show any difference between the three groups ( Figure 2C ). These findings show that antiatherogenic action of adipose tissue transplantation is BAT-specific and is independent of lipid-lowering effect.
BAT transplantation elevates brown adipocyte-related gene expression in endogenous BAT
We next examined the characteristics of grafted and endogenous BAT in apoE 2/2 recipient mice transplanted with wild-type BAT. Bilateral eWAT was dissected and then grafted BAT was extracted by carefully scraping off the surrounding eWAT ( Figure 3A) . The histomorphological examination of the grafted BAT showed unilocular, but not multilocular, droplets like WAT ( Figure 3B) . Consistently, the expressions of brown adipocyte-related genes such as UCP-1, Ppargc1a, Cebpb, Cidea, and Elovl3 were significantly lower than those in endogenous BAT ( Figure 3C ). In contrast, brown adipocyte-related genes expression in endogenous BAT were markedly increased in BAT-transplanted mice compared with those in sham control mice ( Figure 3C ); although histological analysis showed no discernable difference ( Figure 3B ). These findings suggest that functional modulation of endogenous BAT is exerted by BAT transplantation, which is consistent with the improved glucose tolerance and increased whole-body energy expenditure observed in BATtransplanted mice. 6 BAT has also been reported to produce and release endocrine factors 6 ; therefore, we examined the mRNA expression of anti-inflammatory cytokines indicative of atherosclerosis development. Endogenous BAT in BAT-transplanted mice showed a 2.9-fold increase in FGF-21 mRNA expression compared with that of sham control mice, while the mRNA expression profiles of pro-inflammatory cytokines did not differ ( Figure 3D and E) . The grafted BAT showed significant increases in mRNA expressions of both pro-and anti-inflammatory cytokines. We Anti-atherogenic effect of brown adipose tissue 
FGF-21 concentrations in endogenous
BAT and blood are elevated in BATtransplanted apoE À/À mice FGF-21 concentrations in endogenous BAT were significantly higher in BAT-transplanted mice than those in sham control mice, whereas grafted BAT was undetectable ( Figure 4A) . Consistently, circulating levels of FGF-21 in BAT-transplanted mice were significantly higher than those in sham control mice ( Figure 4B) , which was strongly correlated with endogenous BAT, but not grafted BAT, concentration ( Figure 4C ). In contrast, mRNA and protein expression levels in the liver, the dominant source of FGF-21, 14 did not differ ( Figure 4D and E), and there was no significant correlation between liver and serum concentrations of FGF21 ( Figure 4F ), suggesting that endogenous BAT-derived FGF-21 contributes to the elevation of circulating FGF21 levels. We also examined circulating levels of anti-and pro-inflammatory cytokines. The serum TNF-a concentration before BAT transplantation was significantly lower than those after BAT transplantation ( Figure 4G) , showing that serum TNF-a concentration was significantly increased after BAT transplantation; however, no difference could be observed between the two groups. Likewise, there was no difference in the circulating levels of IL-6, IGF-1, and TGF-b between groups ( Figure 4G ), although their mRNA expression levels were markedly increased in grafted BAT ( Figure 3D and E).
Circulating adiponectin is elevated in BAT-transplanted apoE À/À mice
To elucidate the underlying mechanism by which elevated circulating FGF-21 contributes to reduced atherosclerosis in BAT-transplanted mice, we measured circulating concentrations of adiponectin. FGF-21 has been reported to promote the differentiation and lipolysis of WAT, thereby contributing to the augmented production of adiponectin, 15, 16 which could inhibit atherosclerosis development. 17 We examined mRNA expression of white adipocyte-related genes in inguinal WAT (iWAT). As expected, iWAT showed significant increases in SREBP-1c and ATGL gene expression, as well as adiponectin, in BAT-transplanted mice ( Figure 5A ), accompanied by significant reduction in pad weight and adipocyte size ( Figure 5B and C) . Consequently, tissue and serum concentrations of adiponectin were significantly higher in BAT-transplanted mice than those in sham control mice ( Figure 5D and E). Furthermore, serum concentrations of adiponectin were significantly correlated with the percentages of atherosclerotic lesion area ( Figure 5F ), suggesting that an increase in circulating levels of adiponectin potentially contributes to decreased atherosclerosis development in BAT-transplanted mice.
Blockade of b3-AR abolishes the antiatherogenic effect of BAT transplantation
We further examined the mechanism of enhanced production and release of FGF-21 from endogenous BAT after BAT transplantation. Considering the mRNA expression levels of UCP-1 and Ppargc1a in endogenous BAT were significantly elevated in BAT-transplanted mice ( Figure 3C ), brown adipocyte was likely stimulated via the sympathetic nervous system (SNS). Consistently, serum noradrenaline concentration was significantly elevated in BAT-transplanted mice compared with sham control mice ( Figure 6A) . However, no difference could be observed between age-matched non-operated mice and sham control mice ( Figure  6A ), suggesting that SNS activity is not augmented in sham control mice.
To examine the contribution of b3-AR-mediated activation of endogenous BAT in BAT-transplanted mice, nonselective b3-AR blocker or vehicle was administered post BAT transplantation. Although the nonselective b3-AR blocker treatment did not affect the development of atherosclerosis in sham control mice, it augmented development in BAT-transplanted mice to the extent comparable with sham control mice ( Figure 6B and C) . Similarly, serum concentrations of FGF-21 and adiponectin, as well as tissue concentrations were not affected by the nonselective b3-AR blocker treatment in sham control mice; however, those in BAT-transplanted mice were reduced to the extent observed in sham control mice ( Figure 6D and E) . Mean body weight, cumulative caloric intake, hemodynamic parameters, and lipid profiles did not differ between the two groups of mice receiving the nonselective b3-AR blocker treatment (see Supplementary material online, Figure S4 ). These findings strongly support the notion that b3-AR-mediated activation of endogenous BAT plays a crucial role in the anti-atherogenic effect observed in BAT transplantation through activation of the FGF-21-adiponectin axis.
Discussion
In this study, we demonstrated for the first time that transplantation of interscapular BAT of wild-type mice significantly inhibited atherosclerosis development in whole aortas of apoE 2/2 mice. A substantial increase in circulating FGF-21, which was produced and released from activated endogenous BAT, but not from the grafted BAT and liver, could contribute to anti-atherogenic action with simultaneous elevation of circulating adiponectin released from iWAT. Treatment with the non-selective b3-AR blocker completely abolished the anti-atherogenic effect of BAT transplantation concomitant with reduction of circulating FGF-21 and adiponectin. Our findings support the notion that activated BAT could function as an endocrine organ capable of exerting anti-atherogenic action, at least in part, by SNS-mediated stimulation of the FGF-21-adiponectin axis. The key findings of the hypothesized mechanisms are shown in Figure 7 .
The effects of activated BAT on atherosclerosis has been extensively investigated in rodent models. [8] [9] [10] A recent study by Berbée et al. 9 demonstrated that BAT activation by b3-AR agonist treatment inhibited atherosclerotic development in APOE*3-Leiden.CETP mice through a cholesterol-lowering effect; however, this was not the case in apoE
and LDLR 2/2 mice presumably due to the defective clearance of remnant LDL-cholesterol via the apoE-LDLR-dependent pathway in the liver. Likewise, Dong et al. reported that BAT activation by cold exposure increased atherosclerotic plaque area in apoE 2/2 mice along with increased remnant LDL-cholesterol levels. 8 These studies investigated the anti-atherogenic action of activated BAT in terms of the altered lipid profiles attributable to an increase in energy expenditure. Notably, BAT has recently been identified as an endocrine organ capable of secreting a number of endocrine factors, such as FGF-21, IGF-1, IL-10, etc., which could affect atherosclerosis development as well as glucose and lipid homeostasis. 11 A recent study by Stanford et al. 6 showed that BAT transplantation activated endogenous BAT to produce and release FGF-21, thereby contributing to the improvement of glucose tolerance and insulin resistance. We also showed the possibility that endogenous BATderived FGF-21 could exert an anti-atherogenic action concurrently with elevation of circulating adiponectin without affecting cholesterol levels, indicating that BAT could be a potential therapeutic target for the prevention of atherosclerotic and metabolic diseases. FGF-21 is an endocrine factor dominantly released into the circulation from the liver and BAT, and exerts beneficial effects on glucose and lipid metabolism. 14, 18, 19 Although FGF-21 mRNA levels in iWAT as well as liver did not differ between the two groups (see Supplementary material online, Figure S5 ), much attention has recently been focused on the FGF-21 expression in the acinar pancreas. 20 Pancreas FGF-21 expression in BAT transplanted mice need to be investigated in future studies. Recently, Lin et al. 21 showed that atherosclerosis development was exaggerated in FGF-21 and apoE double knockout mice, and mostly reversed by recombinant FGF-21 treatment. FGF-21 has been reported to have cholesterol-lowering effects by reducing hepatic cholesterol production. 22 Therapeutic administration of FGF-21 has been reported to improve lipid profiles in both animal and clinical studies. 23, 24 In this study, cholesterol levels were comparable between BAT-transplanted and sham control mice, indicating that FGF-21-mediated cholesterollowering effects are unlikely to contribute to the anti-atherogenic effect of BAT transplantation. Recently, FGF-21 has been shown to promote 'browning' of white adipocytes to increase energy expenditure 25 ; however, mRNA expression levels of UCP-1 and Ppargc1a in iWAT were comparable in BAT-transplanted and sham control mice, suggesting that 'browning' of iWAT is less implicated in the anti-atherogenic effect of BAT transplantation. FGF-21 is a potent stimulator of adiponectin production in adipose tissue possibly by PPARc activation. 26, 27 Adiponectin has been shown to exert direct anti-atherogenic action on all major blood vessel cells and modulate both innate and adaptive immunity involved in plaque formation. 17 Adiponectin gene and protein expression were significantly increased in iWAT, leading to elevation of serum adiponectin levels, which were inversely correlated with atherosclerotic lesion area. These findings show a strong correlation between BAT transplantation and activation of FGF-21-adiponectin axis; however, causal mechanism should be investigated using genetically modified mice.
In the earlier studies to investigate the effect of adiponectin on atherosclerosis, plaque size in the aortic root seems to be critical. The gain-offunction study by Nawrocki et al. 28 did not show any effect on advanced plaque area, while the loss-of-function study by Okamoto et al. 29 showed a significant progression in the early stage of atherosclerosis. Adiponectin has been reported to upregulate eNOS expression and promote NO production in endothelial cells and to inhibit leukocyteendothelium interaction, 30, 31 suggesting that anti-atherogenic action of adiponectin is likely to exert in the early stages rather than the advanced stages of atherosclerosis. In the current study, mean plaque area in the aortic root was correspond to the advanced plaque lesions (0.71 ± 0.05 vs. 0.70 ± 0.04 mm 2 , Sham vs. Trans), which may contribute, at least in part, to the absence of anti-atherogenic effect of BAT transplantation on aortic root lesions.
Hanssen et al. 32 demonstrated that circulating FGF-21 levels are positively correlated with BAT activity during acute cold exposure in human volunteers, and that chronic cold acclimation increases BAT activity in parallel with an increase in FGF-21 levels. BAT is densely innervated with sympathetic neurons, 33 and their activation after BAT transplantation is detected by measuring norepinephrine turnover rates. 34 A recent study by Berbée et al. 9 demonstrated that BAT activation by b3-AR agonist treatment inhibited atherosclerotic development in APOE*3-Leiden.CETP mice. Taken together, BAT activation via b3-AR seems to play a crucial role for preventing atherosclerotic disease as well as metabolic disorders. Consistently, nonselective b3-AR blocker treatment completely abolished the anti-atherogenic effect of BAT transplantation concomitant with reduced concentrations of circulating FGF-21 and adiponectin. However, nonselective b3-AR blocker SR59230A has a very similar affinity for b1-, b2-, and b3-AR ( 8.6, 9.3, and 6.9-8.4 pKi, respectively, IUPHAR database: http://www.guidetopharmacology.org/ (9 November 2017, date last accessed)). Furthermore, Zhu et al. 34 reported that BAT transplantation significantly increased SNS activity in mesenteric WAT, while it was unchanged in inguinal, epididymal, and retroperitoneal WAT, suggesting that BAT transplantation activates SNS networks in a tissue-and depot-specific manner. Collectively, b-AR activation by BAT transplantation plays a role in inhibition of atherosclerosis, but we cannot exclude the possibility that activation of b-AR in other tissues could be involved directly or indirectly. We also observed that treatment with nonselective b3-AR blocker SR59230A did not affect atherosclerosis development in sham control mice, which is consistent with the findings by Wang et al. 35 Considering that SNS activity in sham control mice is not augmented and that tissue and serum concentration of FGF-21 is not changed by treatment with nonselective b3-AR blocker, excessive SNS activation in BAT-transplanted mice contributes to the reduction of atherosclerosis development.
Stanford et al. 6 demonstrated that wild-type BAT-transplanted mice showed a significant increase in circulating FGF-21 levels, which was completely abolished in IL-6 deficient (IL-6
) BAT-transplanted mice, accompanied by decreased concentrations of circulating IL-6. Considering that IL-6 can cross the brain blood barrier and intracerebroventricular administration of IL-6 increases sympathetic outflow, 36 grafted BAT-derived IL-6 is considered to be of importance for endogenous BAT activation in BAT-transplanted mice. In support of this notion, Wernstedt et al. 37 showed that stress-and cold-induced increases in energy expenditure were reduced in IL-6 2/2 mice. Knudsen et al. 38 also
showed that a cold exposure-induced increase in iWAT UCP1 protein content was blunted in IL-6 2/2 mice. Thus, we examined circulating IL-6 levels; however, they were equivalent between BAT-transplanted and sham control mice, which was in agreement with the results by Liu X et al. 7 The most critical difference between the findings of Stanford et al. and ours is that sham control mice in their study show much lower circulating IL-6 levels when compared with this study, because wild-type mice in their study were fed a standard diet, while apoE 2/2 mice were fed a high-cholesterol diet in the current study. Considering that circulating IL-6 levels derived from the aortic wall are increased along with the progression of atherosclerosis, 39, 40 it is likely that advanced stage of atherosclerosis development in sham control mice makes it difficult to find the difference in circulating IL-6 levels between the two groups at the time point we examined. Although we could not see the increased serum levels of IL-6, pro-inflammatory response in grafted BAT may play a key role in the activation of endogenous BAT, rather than as a source of FGF-21. Neurochemical pathways and mediators through which they influence BAT activity after BAT transplantation should be further investigated in future studies.
In conclusion, our results showed that BAT activation elicited by BAT transplantation substantially attenuates atherosclerosis development in apoE 2/2 mice, at least in part, via SNS-mediated activation of the FGF-21-adiponectin axis. Our findings shed new light on the emergence of BAT activation as an endocrine organ and suggest that BAT-specific activation may be a useful therapeutic strategy for the prevention of cardiovascular diseases.
Supplementary material
Supplementary material is available at Cardiovascular Research online. 33,34 (B) Activated BAT produces and releases endocrine factors. 11 In particular, BAT transplantation has been reported to activate endogenous BAT, leading to the production and release of FGF-21. 6 (C) FGF-21 is a potent stimulator of adiponectin production in adipose tissue possibly by PPARc activation. 26, 27 (D) Adiponectin has been shown to exert direct anti-atherogenic action on all major blood vessel cells and modulate both innate and adaptive immunity involved in plaque formation.
